Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorLópez Cortés, Luis
dc.contributor.authorLuque-Pardos, Sonia
dc.contributor.authorFernandez Polo, Aurora
dc.contributor.authorHerrera Hidalgo, Laura
dc.contributor.authorde Alarcón González, Arístides
dc.contributor.authorFernández-Rubio, Beatriz
dc.contributor.authorLuque-Marquez, Rafael
dc.date.accessioned2023-04-05T10:29:40Z
dc.date.available2023-04-05T10:29:40Z
dc.date.issued2023-03
dc.identifier.citationFernández-Rubio B, Herrera-Hidalgo L, Luque-Márquez R, de Alarcón A, López-Cortés LE, Luque-Pardos S, et al. Stability of Ampicillin plus Ceftriaxone Combined in Elastomeric Infusion Devices for Outpatient Parenteral Antimicrobial Therapy. Antibiotics. 2023 Mar;12(3):432.
dc.identifier.issn2079-6382
dc.identifier.urihttps://hdl.handle.net/11351/9308
dc.descriptionAmpicillin; Infective endocarditis; Outpatient parenteral antimicrobial therapy
dc.description.abstractCurrently, ampicillin plus ceftriaxone (AC) is one of the preferred treatments for Enterococcus faecalis infective endocarditis. However, there is a lack of stability data for the combination of both drugs in elastomeric devices, so the inclusion of AC in Outpatient Parenteral Antimicrobial Therapy (OPAT) programs is challenging. The objective of the study was to determine the stability of AC in elastomeric pumps when stored at 8 ± 2 °C, 25 ± 2 °C, 30 ± 2 °C and 37 ± 2 °C using LC-MS/MS. The combination was diluted in 0.9% sodium chloride and the final concentrations were ampicillin 24 g/L plus ceftriaxone 8 g/L. Physical and chemical stability were evaluated at 12, 20, 24, 36 and 48 h after preparation. Stability was met at each time point if the percentage of intact drug was ≥90% of its respective baseline concentration and color and clearness remained unchanged. The drug combination was stable for 48 h when it was kept at 8 ± 2 °C. At 25 ± 2 °C and 30 ± 2 °C, they were stable for 24 h of storage. At 37 ± 2 °C, the stability criterion was not met at any time point. These results prove that AC could be included in OPAT programs using elastomeric infusion devices for the treatment of E. faecalis infections.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesAntibiotics;12(3)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMedicaments antibacterians - Ús terapèutic
dc.subjectEndocarditis bacteriana - Tractament
dc.subject.meshEndocarditis, Bacterial
dc.subject.mesh/drug therapy
dc.subject.meshAnti-Bacterial Agents
dc.subject.mesh/therapeutic use
dc.titleStability of Ampicillin plus Ceftriaxone Combined in Elastomeric Infusion Devices for Outpatient Parenteral Antimicrobial Therapy
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/antibiotics12030432
dc.subject.decsendocarditis bacteriana
dc.subject.decs/farmacoterapia
dc.subject.decsantibacterianos
dc.subject.decs/uso terapéutico
dc.relation.publishversionhttps://doi.org/10.3390/antibiotics12030432
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Fernández-Rubio B] Unidad de Gestión Clínica de Farmacia, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBiS), Seville, Spain. [Herrera-Hidalgo L] Unidad de Gestión Clínica de Farmacia, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBiS), Seville, Spain. Unidad de Gestión Clinica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBiS), Seville, Spain. [Luque-Márquez R, de Alarcón A] Unidad de Gestión Clinica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBiS), Seville, Spain. [López-Cortés LE] Infectious Diseases and Microbiology Clinical Unit, University Hospital Virgen Macarena, Departament of Medicine, School of Medicine, University of Sevilla, Biomedicine Institute of Sevilla (IBiS)/CSIC, Seville, Spain. Centro de Investigación en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. [Luque-Pardos] Unidad de Gestión Clínica de Farmacia, Hospital del Mar, Barcelona, Spain. [Fernández-Polo A] Servei de Farmàcia, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid36978299
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record